A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

When you’re on GLP-1 medications that constant nagging about hunger and cravings, also known as “food noise” finally quiets ...

Researchers in China may have uncovered a surprising ally in the fight against sugar cravings and metabolic disorders: a ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral ...